January 03, 2018
Rose
Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge Builder’s Collaborative.
from MobiHealthNews http://ift.tt/2CAhQoy
January 03, 2018
Rose
MobiHealthNews
No comments
Related Posts:
Care coordination tool SCI Solutions acquires digital health tools company DatStat- Virta Health brings in $45M for online T2D therapy
- Education, engagement company MedBridge receives funds for growth, expansion
- Rock Health and StartUp Health agree Q1 2018 was digital health's biggest quarter yet
- Millennials demand telehealth in a move away from traditional primary care model
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment